Steatohepatitis/Metabolic Liver Disease News

Nonalcoholic fatty liver disease correlated with an approximately 90% higher risk for liver and gastrointestinal cancers compared with patients without fatty liver disease, while the association between obesity without fatty liver disease and cancer was small.

Increases in liver fat correlated with development of cardiovascular disease risk factors including incident diabetes and metabolic syndrome, according to results from a 6-year longitudinal study.

Autoimmune liver diseases include primary biliary cholangitis, primary sclerosing cholangitis, and pediatric diseases such as biliary atresia and progressive familial intrahepatic cholestasis. Researchers continue to investigate and develop potential treatments for both the diseases and their debilitating complications.

Nonalcoholic fatty liver disease fibrosis scores and Fibrosis-4 index scores increased longitudinally and at a higher rate in those with fatty liver and fibrosis stage 2 or higher compared with those with stage 1 or no fibrosis, according to data.

Abnormal glucose tolerance, especially prediabetes, was highly prevalent among children and adolescent patients with established nonalcoholic fatty liver disease, according to a recently published study.

Liver disease in children and adolescents takes on as many forms as in adults, including viral hepatitis, autoimmune diseases, fatty liver disease, and even the pediatric-specific biliary atresia that occurs in infants.

Interim results of an ongoing phase 1 clinical trial of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor for the treatment of nonalcoholic steatohepatitis, revealed a positive safety and tolerance profile, according to a press release from Terns Pharmaceuticals.

Use of an automated investigation algorithm known as intelligent liver function testing increased liver disease diagnoses and improved patient quality of care in a cost-effective manner, according to a study published in Journal of Hepatology.

89Bio launched a proof of concept phase 1b/2a clinical trial of BIO89-100 for the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis with the first patient screened, according to a press release.

Light to moderate alcohol intake correlated with a decreased risk for simple hepatic steatosis in patients without nonalcoholic fatty liver disease, whereas the same consumption in those with nonalcoholic fatty liver disease and those with obesity had an increased risk, according to recently published data.